Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
Academic Article
Publication Date:
2021
Short description:
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV / González-Cordón, Ana; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Stellbrink, Hans-Jürgen; Guaraldi, Giovanni; Masiá, Mar; Gompels, Mark; De Wit, Stephane; Florence, Eric; Esser, Stefan; Raffi, François; Behrens, Georg; Pozniak, Anton; Gatell, José M; Martínez, Esteban. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 76:9(2021), pp. 2380-2393. [10.1093/jac/dkab158]
abstract:
Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown.
Iris type:
Articolo su rivista
List of contributors:
González-Cordón, Ana; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Stellbrink, Hans-Jürgen; Guaraldi, Giovanni; Masiá, Mar; Gompels, Mark; De Wit, Stephane; Florence, Eric; Esser, Stefan; Raffi, François; Behrens, Georg; Pozniak, Anton; Gatell, José M; Martínez, Esteban
Published in: